<DOC>
	<DOCNO>NCT01275469</DOCNO>
	<brief_summary>The purpose study evaluate efficacy GFT505 80mg compare placebo improve Oral Glucose Tolerance Test ( OGTT ) , patient impair glucose tolerance abdominal obesity , assess tolerability safety once-a-day administration oral dos GFT505 35 day .</brief_summary>
	<brief_title>Pilot Study With GFT505 ( 80mg ) Patients Presenting With Impaired Glucose Tolerance Abdominal Obesity .</brief_title>
	<detailed_description>The study period 13 week maximum per patient : A screening period ( 1 6-weeks ) precede 5-week double-blind treatment period 2-week follow-up period . The duration screen period depend necessity introduce wash-out lipid-lowering drug : 4-week wash-out statin lipid regulate drug 6-week wash-out fibrates . During screen period , patient ask start continue adequate diet exercise .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<criteria>Male postmenopausal female . Waist circumference ≥94cm male , ≥ 80cm female . Fasting Plasma Glucose ( FPG ) 110 126 mg/dl ( 6.1 7.0 mmol/l ) within 6 month prior screen visit . 2hour glycaemia OGTT ( 2hr 75g oral glucose load ) ≥140 mg/dL ( 7.8 mmol/l ) . Body Mass Index ( BMI ) ≥ 40 kg/m² . Blood Pressure &gt; 160 / 95 mmHg . Known Type I type II Diabetes Mellitus . Glycated haemoglobin ( HbA1c ) &gt; 7 % . A fasting TG &gt; 400mg/dl LDLC &gt; 220mg/dl .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Impaired Glucose tolerance</keyword>
	<keyword>OGTT</keyword>
	<keyword>PPARs</keyword>
</DOC>